Recently, it has been shown that the overexpression of CDCP1 in AML patients, receiving high dose of anthracycline within the induction therapy, constitutes a negative prognostic factor, generally more expressed in undifferentiated AML phenotypes (M0, M1) [27]. This evidence concerns the gene CDCP1 and acute myeloid leukemia.